pharma · Cholestatic liver disease · Cystic Fibrosis · PRQR
ProQR Therapeutics N.V
ProQR Therapeutics N.V.
ProQR Therapeutics is a pharma organization headquartered in Leiden, NL. It trades on NYSE under ticker PRQR. Primary therapeutic focus areas include Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinit
Leiden, NL HQ
2012 Founded
204 Employees
Public company Type
PRQR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Leiden, NL
- Founded
- 2012
- Employees
- 204
- Programs
- 6
- Drugs
- 2
- Patents
- 19
QR-504a
Phase 1 · small molecule · Fuchs Endothelial Corneal Dystrophy
QR-504a for Fuchs Endothelial Corneal Dystrophy is a Phase 1 program (small_molecule) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).
Internal code PQ-504a-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ProQR Therapeutics N.V.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Fuchs Endothelial Corneal Dystrophy
- Status
- terminated
- Trials
- 1